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ABSTRACT 
Radiotherapy in the Management of Carcinoma of the Vulva in Human Immune-Deficiency Virus 
(HIV) Positive and Negative Patients: An Institutional Experience. 
 
Opakas J.  
Department of Medical Imaging and Clinical Oncology, Division of Radiation and Clinical Oncology, 
Tygerberg Academic Hospital and the University of Stellenbosch 
Background: Radiotherapy and chemotherapy are integral parts of the effective and optimal management 
of patients with vulva cancer, especially when initiated early in the course of this disease. Often, surgical 
resection alone cannot effect total removal of the tumour or may not be feasible. 
 
Human Immune-Deficiency Virus (HIV) infection has been an epidemic in sub-Saharan Africa. Highly 
Active Antiretroviral Therapy (HAART) is available in public health facilities in the region to arrest and 
control HIV infection, delaying the progression to AIDS and death. Infection with HIV has now been 
transformed into a manageable, chronic disease and this has allowed patients to live longer, healthier and 
more productive lives. 
 
 Human Immune-Deficiency Virus (HIV) infection may further complicate the management of vulva 
cancer disease as patients are immunocompromised and may have difficulty in completing treatments 
prescribed. 
 
This study aims to identify and assess the outcomes, tolerances, toxicities and factors influencing 
treatment completion in both HIV positive and negative patients with vulva cancer treated at Tygerberg 
Academic Hospital. 
 
Study Design and Methods: This is a retrospective, observational, cross-sectional review of the factors 
influencing the completion of radical radiotherapy in the treatment of locally advanced cancer of 
the vulva. Patients are classified as either HIV positive or HIV negative. The period of the study was 
between 1
st
. January 2007 and 31
st
 December 2012 and it was conducted at the Division of Radiation 
Oncology, Tygerberg Academic Hospital, Cape Town, South Africa. 
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All the HIV positive patients were already on antiretroviral therapy at the outset. The disease and 
treatment characteristics are described as well as toxicities of treatment of patients undergoing 
radiotherapy and chemo-radiation. 
Treatment completion for the two groups is evaluated. The toxicities that led to treatment interruptions for 
these groups are also listed. 
Results: Of the 68 patients screened, 25 met inclusion criteria; of these patients, seven (28%)  were HIV 
positive while the other 18 (72%) were negative. Vulva cancer patients infected with HIV presented at a 
younger age and with more locally advanced tumours compared to HIV negative patients. There is no 
statistically significant difference between the two groups in treatment completion rates and tumour 
failure rates. 
Conclusion: 
This retrospective study concludes that HIV positive patients with vulva cancer presented with a more 
locally advanced disease and at a younger age when compared to HIV negative patients. There was no 
statistically significant difference in overall therapeutic outcomes although cutaneous toxicities were 
more pronounced in the HIV positive subset. Chemo-radiotherapy sequentially or concurrently can be 
regarded as a standard of care in both HIV positive and negative patients provided that the HIV patients 
are on antiretroviral therapy. 
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Chapter 1: 
Introduction and Background 
This paper provides a retrospective review of the profile of patients who commenced radical treatment for 
vulva carcinoma at Tygerberg Hospital’s Division of Radiation and Clinical Oncology between 1st 
January 2007 and 31
st
 December 2012.  It examines the demographic and disease characteristics of these 
patients and also the percentage who completed the planned treatment and as far as possible the outcomes 
thereof. The study notes the HIV status of the patients in relation to the abovementioned characteristics.  
Descriptive  statistics are used in view of the relatively low numbers of eligible patients and comparisons 
are drawn with similar publications from other centers. 
 
Carcinomas of the vulva are rare, accounting only for about 2-4% of gynecologic malignancies and 0.6% 
of all cancers in women; consequently, published institutional reviews are relatively rare even though 
these are needed to assess efficacy of treatment and to make comparisons 
(1)
 . Thus, more work is needed 
to understand the disease better and to contribute to the body of knowledge regarding treatment and 
control strategies. 
 
 All the patients in this study were treated with radiation with or without chemotherapy concurrently or 
sequentially; all treatment was in line with departmental protocol unless otherwise stated. 
 
Chemo-radiation for vulva cancer produces signiﬁcant acute morbidity, which has been well documented 
(2)
 , but far less is known about the effects of HIV positivity in patients and if this could influence 
treatment related morbidity, quality of life and overall outcomes in HIV positive patients. 
 
Treatment 
 
At Tygerberg Hospital the patients are managed as per the Western Cape protocol for Gynecological 
malignancies 
(3)
 . 
 
On evaluation of a confirmed malignant vulval lesion, the treatment algorithm is as shown below. 
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Treatment Flow Chart, Figure 1 
 
 
 
Post-operatively, If all nodes are histologically negative, the patient is then followed up  with clinical 
examinations three monthly for the first two years then six monthly until five years. If there are positive 
ipsilateral lymph nodes, then the patient is offered contralateral groin dissection.  
 
If the patient still has positive nodes or close margins the patient is then offered adjuvant therapy with 
further excision either with or without chemo-radiation  
 
If the patient presents with clinically positive locally advanced disease, neoadjuvant chemo-radiation is 
administered to downsize the tumour and make it amenable for less debilitating surgery. 
Histological / Cytological 
Diagnosis 
Microinvasive disease < 
1mm invasion, ≤ 2cm in 
size and no 
lymphovascular invasion 
Wide Local excision with 
1cm margin 
Invasive disease more 
than 1mm invasion 
Lateralised > 1cm from 
midline 
Radical excision and  
ipsilateral groin nodal 
dissection 
Midline lesion ≤ 1cm from 
Midline or > 2cm in size 
and > 5mm invasion 
Radical excision and 
bilateral groin nodal 
dissection 
Locally advanced disease 
with clinically positive 
groin nodes 
Consider Neoadjuvant 
chemoradiation 
Distant  Metastases 
Consider Palliative 
chemotherapy and local 
radiotherapy as needed 
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Patients who present with metastatic disease may be considered for palliative chemotherapy and local 
radiotherapy as appropriate. 
 
Approach to Radiotherapy: 
 
Radiotherapy specifically involves individualizing target volume but includes in most cases the vulva, 
groin and pelvic nodes.  
 
Typically, a pair of anterior posterior parallel-opposed portals are used. A dosage of 2.5 Gray daily, five 
times per week for two weeks is administered (25 Gray mid plane dose). 
 
A re-assessment is made two weeks later, having allowed for settling of any perineal skin reaction and 
regression of tumour. If nodal disease is not present, and sufficient regression of the primary tumour has 
occurred, wide local excision is performed. 
 
If regression of the primary tumour is insufficient, a repeat course of chemo-radiation may be given at an 
additional dosage of 20 Gray in ten fractions.  A reassessment is made two to three weeks later. 
 
Every attempt is made to excise residual tumour. If regression is complete, a biopsy of the tumour bed is 
done to confirm eradication of the tumour. 
 
If surgery is not possible, or extensive residual nodal disease is present, small volume booster doses of 
15-20 Gray are applied to any residual tumour. 
 
An alternative approach to fractionation is to treat to 45 Gray in 25 fractions to the larger volume and a 
booster dose up to 20 Gray in 1.8 – 2 Gray fractions as appropriate over a 6-week period with or without 
weekly chemo-sensitization with cisplatin. 
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Literature Review 
A systematic search was performed using the databases of PubMed, Ovid, Embase, Google Scholar and 
the Cochrane Library  to identify relevant publications produced between 1960 and the current time of 
writing. Publications deemed relevant were those reporting on studies of patients with Human Immune-
Deficiency Virus (HIV) infection and vulva cancer who were treated with radiotherapy and chemotherapy 
concurrently or sequentially. 
Acquired Immune-Deficiency Syndrome (AIDS) was found to be caused by Human Immune-Deficiency 
Virus (HIV) Infection and has been an epidemic in sub-Saharan Africa for the past two decades 
(4)
 . 
Highly Active Antiretroviral Therapy (HAART) is now generally available in public health institutions 
and this treatment has had a major impact in controlling HIV infection, delaying the progression to AIDS 
and death 
(5) 
.  Infection with HIV has now been transformed into a manageable, chronic disease. 
Donahue et al. (1989)  argue that HIV infection in malignant disease can be managed as a chronic disease 
while on HAART or a more virulent disease without treatment 
(6)
.  In consequence, infected individuals 
on HAART could potentially have improved outcomes when treated for their cancers as morbidity from 
competing opportunistic infections declines. 
The management of patients with locally advanced vulvar cancer in itself is a therapeutic challenge to 
both the patient and the radiation oncologist due to the location of the tumour and organs involved   
(7)
.  
In the background of HIV infection, patients could be confronted with multiple competing conditions and 
sequels making it necessary to pursue the most effective therapy with a minimal toxicity profile  
(8)
 . 
According to Cottrill et al. (1997), a multidisciplinary approach is essential in treatment and management  
(2)
 . 
Primary exenterative surgery was the traditional approach for locally advanced disease, which 
necessitated colostomy and/or urinary diversion with debilitating morbidity and mortality and a poor 
quality of life for patients. 
Initial studies by Boronow et al. (1987) explored the efficacy of a combined radiation-surgical approach 
with encouraging results obtained from a sample of 48 treated cases (37 primary cases and 11 cases of 
recurrent disease). This suggested that a combined therapeutic approach of radiotherapy and surgery as 
opposed to exenterative surgery alone, could lead to a high probability of bladder and/or rectal 
preservation, low primary mortality, low treatment morbidity with very good cancer control
(11)
. 
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Other authors such as Hruby et al. (2000)  in Australia advocated for concurrent neo-adjuvant chemo-
radiation with planned surgery if any residual disease should become resectable. This was proposed as a 
way to achieve maximum benefit in unresectable disease as opposed to surgery alone 
(7) 
. 
Based on these trials and other independent studies extrapolated from cervical cancer the Gynecological 
Oncology Group (GOG) protocol 101 studied cisplatin plus 5-fluorouracil chemo-radiation for the 
preoperative treatment of 71 patients with locally-advanced squamous cell carcinoma of the vulva which 
was not amenable to standard surgical resection. The intention was to evaluate prospectively the efficacy 
of chemo-radiotherapy in reducing the extent of surgical morbidity with acceptable toxicities of treatment. 
(12)
  Of these patients, 46.5% had no visible vulvar cancer at the time of planned surgery and 53.5% had 
gross residual cancer at the time of operation. 
Thirteen percent of the latter patients with gross residual cancer had positive resection margins and 
underwent further radiation therapy to the vulva. 
 Using this strategy of preoperative, split-course, twice-daily radiation combined with cisplatin plus 5-
fluorouracil chemotherapy, only two of the 71 patients had residual unresectable disease. 
 In only three patients was it not possible to preserve urinary and/or gastrointestinal continence. 
 The toxicity profile was acceptable, with acute cutaneous reactions to chemo-radiotherapy and surgical 
wound complications being the most common adverse effects. 
A follow-up Phase Two trial Gynecological Oncology Group (GOG) 205 was initiated which specified 
cisplatin 40 mg/m
2
 (to max dose 70 mg) weekly and concurrent to radiation therapy; this approach was 
borrowed from cervical cancer studies
(13)
. 
Phase Two evaluated 58 patients of whom 40 (69%) completed the study treatment. There were 37 
patients with a complete clinical response (37/58; 64%). Among these women there were 34 who 
underwent surgical biopsy and 29 (78%) who also had a complete pathological response.  
The common adverse effects included leukopenia, pain, radiation dermatitis and metabolic changes. 
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This Phase Two study eliminated a planned treatment break. It delivered a higher total dose of radiation 
(20% escalation in dose over GOG protocol 101) to the primary tumour with an impressive outcome: the 
findings suggest that neo-adjuvant chemo-radiation for unresectable locally advanced vulva carcinoma 
should be the standard of care followed by surgical excision of residual disease if possible 
(13)
. 
Studies by Watkins et al. (1987) focused on reactions presenting in the head and neck and the findings 
suggested that HIV positive patients may have an enhanced oral mucosal radiosensitivity and may 
develop severe oral mucosal reactions at a lower dose than HIV negative patients. This could influence 
the completion of treatment by patients judged capable of tolerating a radical course of radiotherapy:  this 
has however not been reported in literature on vulva cancer as far as our literature search can establish 
(14).
  
A clinico-pathological review of five cases of HIV infected patients with vulva cancer is reported by 
Sekowski et al. (2008). Their review covers cases from Polokwane, South Africa and describes responses 
to radiotherapy alone and one case of concomitant chemo-radiation with good responses and acceptable 
toxicity 
(15)
. 
Rogers et al. (2009) reported on a retrospective study of 50 women treated with chemo-radiation for 
advanced vulva cancer during the period 1982 to 2001.  Fourteen (28%) of the women had a complete 
response while 29 (58%) had a partial response.  Of these, seven women underwent post-radiation surgery 
with a significantly better survival outcome. HIV sero-positivity and response to therapy in these patients 
were not discussed in this study
 (16)  
. 
To the best of the writer’s knowledge, it appears that except for a few isolated case reports, there have 
been few studies of the management of locally advanced vulva cancer in a background setting of HIV 
infection, using radiotherapy with or without sequential or concomitant chemotherapy. Certainly, this 
issue has never been studied sufficiently to provide a specific treatment model tailored for Sub-Saharan 
Africa and parts of the developing world with similar challenges. 
At best, studies done on the treatment of HIV infected patients with primary cervical and anal cancers 
have been extrapolated to establish guidelines for the treatment of vulva carcinomas regardless of the 
patients’ HIV status. 
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A review of trends in completion of pelvic radiotherapy in HIV positive patients 
As Highly Active Antiretroviral Therapy (HAART) became widely available there have been dramatic 
decreases in HIV mortality.  Concurrently, the incidence of Non-Aids Defining Cancers (NADCs) has 
increased as people with chronic HIV infection survive longer and become older 
(4,6,17)
. Thus, the 
spectrum of NADCs has expanded as the size of the HIV positive population has increased. HIV positive 
patients with pelvic cancer have generally been reported to have a poorer outcome than HIV negative 
patients and typically have more advanced cancers at presentation, relapses, and worse therapeutic 
response. This finding was initially reported by Agarwal et al. in the case of patients who were not on 
antiretroviral therapy to control the infection 
(17)  
. 
In studies of cervical cancer, Gichangi et al. (2005) reported a positive association between HIV infection 
and an increased risk radiation-related toxicity; this would lead to unplanned treatment interruptions and a 
higher probability of pelvic treatment failure with residual disease. It should be noted that this study did 
not indicate whether these patients were on antiretroviral therapy 
(19)
. 
Lomalisa et al. (2000) conducted a retrospective review of 60 HIV positive and 776 HIV negative patients 
with invasive cervical cancer, with the finding that on average, HIV positive patients presented with 
invasive cervical cancer almost ten years earlier than HIV negative patients.   This did not affect the 
extent of disease at presentation nor was there an associated increased incidence of cervical cancer   
(20)
These findings were consistent with Moodley et al. (2005) who conducted studies in Kwa-Zulu Natal on 
the prevalence and outcomes of treatment, arguing that the increased morbidity and mortality in HIV 
positive patients was due to other competing conditions associated with HIV infection 
(8)
  . 
A similar study was conducted by Simonds et al. (2012) on HIV positive patients with cervical cancer 
receiving chemo-radiotherapy.  It found that good medical care of HIV positive patients with  
antiretroviral medication can enable those patients to complete treatment for locally advanced cervical 
cancer as well as the immune-competent patients 
(21)
. The study stressed that it was important for those 
patients to complete radiotherapy. 
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It can be therefore concluded that there is insufficient data on vulva cancer in the presence of HIV co-
infection:  this is primarily due to the rarity of the disease and changing trends with the introduction of 
anti-retroviral therapy, partly as a consequence of this, there is no evidence to suggest that the 
management of vulva cancer in sero-positive and sero-negative patients should not be managed in the 
same way. 
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Chapter 2: Research Design and Methodology 
 
Introduction 
 
Study Aims and Objectives  
 
This study gives a retrospective review of patients who commenced radical treatment for local vulva 
carcinoma using radiotherapy with or without chemotherapy, either concomitant or sequentially as per the 
FIGO definitions (Stage I-III). It describes the various complications in each group of patients and 
specifically examines how each group appears to relate to possible aggravating factors such as HIV sero-
positivity. 
 
 The study also aims to explore any need for adjustments in future protocols and if necessary it suggests 
areas for more detailed examination in any subsequent prospective study. 
 
It reviews patient folders and records sourced from the Division of Radiation Oncology, Tygerberg 
Academic Hospital, Cape Town, South Africa after approval by the Human Research Ethics Committee of 
the University of Stellenbosch and the Western Cape provincial department of Health through the 
Tygerberg Hospital administration. 
 
Eligibility criteria are: 
o Cytologically and/or histologically confirmed primary cancer of the vulva. 
o Locally advanced vulva cancer (Stages I-III). 
o Treatment with radical intent. 
o Patients treated between 1st January 2007 and 31st December 2012. 
 
One exclusion criterion: 
o Previous therapeutic irradiation to the pelvis. 
  
The study reviews patients who met the above-mentioned criteria and who were treated between January 
1, 2007 and December 31, 2012. Patients are grouped according to: HIV status; clinical, demographic and 
disease characteristics; types of chemotherapy and surgery when utilized; treatment time to completion; 
and,  total dose of radiotherapy in two Gray equivalents. The study also records the reasons why patients 
either failed to complete their treatment as prescribed or had it delayed. 
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Responses are assessed by the clinical examination notes as per the new response evaluation criteria in 
solid tumours: Revised (RECIST) guideline (version 1.1) 
(22)
. 
 
HIV positivity was defined as positivity of ELISA laboratory testing of blood samples  during the routine 
pre-intervention work-up. The presentation of the data is followed by a detailed discussion of the findings 
and where possible, comparison to the results derived from similar data collected elsewhere. 
 
Data Capturing and safety 
 
All data were captured in Excel, rendered anonymous on chart abstraction, and were handled and stored 
in a password secure computer. 
Data were analysed in Statistica version 10 (2012) with the help of J. Harvey at the Centre for Statistical 
Consultation, University of Stellenbosch. 
The potential risk of loss of confidentiality was dealt with by using a study number for each patient, with 
grouped patient reporting and password protection.  Only the principal investigator has the recourse to 
link the patient records to the study numbers. 
This was a minimal risk study and justified the use of retrospective data without informed consent. 
Therefore, a waiver of informed consent was requested and was duly granted by the University of 
Stellenbosch Health Research and Ethics Committee. 
Descriptive data analysis was utilized. 
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Chapter 3:  RESULTS 
In total, records of 68 patients with vulva cancer were identified.  Of these, 25 patients met the inclusion 
criteria, notably the criterion of having locally advanced vulva cancer (Stage I-III) and the criterion of 
deemed to have a potential benefit from radiotherapy with or without chemotherapy. 
Amongst ineligible patients, one had rhabdomyosarcoma with lung metastases and the remainder were 
treated palliatively for advanced disease. 
Of the 25 patients treated radically, seven (28%) were HIV positive and 18 (72%) were HIV negative. 
The median age at presentation was 58 years for the sero-negative women and 39 years for sero-positive 
women, with a range of 36 to 89 years. Most women were of mixed race, representing 56% of the total 
patients, 32% were black and 12% were white. This is representative of the local population 
demographics. 
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List of Tables 
Table 1 
HIV- status Positive  Negative 
n = 7 %  n = 18 % 
Median age 
At Diagnosis 
(years) 
39 58 
Range (90
th
 
centiles) 
30-46 38-89 
Ethnic group 
Mixed race 2 29 12 66 
Black 5 71 3 17 
White 0 0 3 17 
ECOG Performance Status 
0 0 0 3 17 
1 2 29 11 61 
2 5 72 4 22 
3 0 0 0 0 
4 0 0 0 0 
FIGO Stage 
Grouping 
0 Tis N0 M0 0  0 0  0 
I: T1 N0 M0 0  0 0  0 
IA: T1a N0 M0 0  0 0 0 
IB: T1b N0 M0 0  0 7 39 
II: T2 N0 M0 1  14 5 28 
 IIIA: T1, T2 N1a, 
N1b M0 
3  43 1 6 
IIIB: T1, T2 N2a, 
N2b M0 
     1 14       1   6 
IIIC: T1, T2 N2c 
M0 
2 29 4 22 
IVA: T1, T2 N3 
M0 
0  0 0 0 
T3 Any N M0 
0  0 0 0 
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Table 2 
HIV- status   Positive     Negative      
   n = 7 %  n = 18 %    
Smoking              
Current   0  0   8 44     
Never   3  43   1 6      
Former   3  43   2 11      
Unknown   1  14   7 39     
           
          
          
          
          
         
           
Upfront Tumour Surgery             
Yes   7 100   16 89     
No   0 0   2 11     
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Table 3 
 
HIV- status 
  
 
 Positive  
  
  
Negative  
    
   n =7 %  n = 18 %    
Treatment Given              
Adjuvant RT   4  57   10 55      
Adjuvant CRT   3  43   6   33     
Definitive RT  0 0  1 6   
Definitive CRT  0 0  1 6   
           
Treatment 
interruptions 
         
Yes  2 29  2 11   
No  5 71  16 89    
          
           
Mean Treatment Time             
OTT (Weeks)   7    6      
Gaps (Days)   2    0.06      
           
Total Radiotherapy Dose        
EQD2 (Grays)  52   49     
         
         
 
 
        
                  
HIV- status         Positive        Negative      
   n =7 %  n = 18 %    
Tumour Failure             
Yes   1  14   4 22     
No   6 86   14 78     
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Table 1: Acute adverse effects in HIV Positive patients 
 
 
 Acute adverse effect 
 
Acute adverse 
effect Grading 
0 1 2 3 4 
Neutropenia 6 0 1 0 0 
Thrombocytopenia 6 1 0 0 0 
Anemia 5 0 2 0 0 
Gastrointestinal 
Nausea and 
Vomiting 
0 5 2   
Urinary Bladder 0 5 2 0 0 
Nephrotoxicity 6 1 0 0 0 
Neurotoxicity 6 1 0 0 0 
Rectum 0 3 4 0 0 
Cutaneous/ Skin 0 3 1 3 0 
 
 
 
 
 
 
Table 2: Acute adverse effects in HIV Negative patients 
 
 
 Acute adverse effect 
 
Acute adverse 
effect Grading 
0 1 2 3 4 
Neutropenia 17 1 0 0 0 
Thrombocytopenia 18 0 0 0 0 
Anemia 14 4 0 0 0 
Gastrointestinal 
Nausea and 
Vomiting 
0 11 7 0 0 
Urinary Bladder 1 12 5 0 0 
Nephrotoxicity 15 3 0 0 0 
Neurotoxicity 18 0 0 0 0 
Rectum 1 12 5 0 0 
Cutaneous/ Skin 0 8 9 1  
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Data analysis 
Of the HIV positive group, 71% were black and 29% were of mixed race. In the HIV negative group 16% 
were black, 67% of the patients were of mixed race and 16 % were white. 
On the issue of performance status using the Eastern Cooperative Oncology Group (ECOG) grading, 28% 
of HIV positive patients had a performance status of 1 and 71% had a performance status of 2.  In the case 
of sero-negative patients, 16 % had a performance status of 0; 61% a status of 1 and 22% a performance 
status of 2. 
In the sero-positive subgroup, 86% of patients presented with at least stage 3 disease while only 34% of 
sero-negative patients presented with stage 3 disease 
All sero-positive (100%) patients had upfront surgery. Of these, 57% had adjuvant radiotherapy alone and 
43% had adjuvant concurrent chemo-radiation. Two patients (29%) had treatment interruptions due to 
severe acute skin reactions with continuous vulva chemo-radiation and a treatment break was permitted to 
allow for healing which increased the mean treatment time to 7.29 weeks.  
The mean total radiotherapy dose in equivalent 2 Gray per fraction (EQD2) was 51.78 Gy (range 44.25 
Gy to 61.95 Gy).  
Following chemo-radiotherapy, six (86%) sero-positive patients had no visible cancer twelve weeks after 
treatment. One HIV positive 36 year-old patient with stage 3c cancer had residual disease confirmed 
histologically and was referred for further salvage surgery with complete excision of the tumour and 
negative nodal disease. 
A total of 88% of the sero-negative patients received upfront surgery. Two patients (11%) did not have 
upfront surgery; one was a 58 year-old patient who presented with stage 3c locally advanced vulva cancer. 
She received 45 Grays in 25 fractions with a boost dose of 12.6Gy/7 fractions and four cycles of weekly 
concurrent chemo-radiation; she showed poor response to treatment and persistent disease twelve weeks 
after completing treatment. She was later palliated with a urinary diversion and a colostomy. 
A second  sero-negative patient with a performance status of 2 who had been on PTB therapy and had 
significant weight loss also presenting with stage 3c disease, received 40Gy in 15 fractions. She was 
found to have lung metastases upon work-up for surgical resection of the primary tumour. It is possible 
that the patient had metastatic disease from the outset. 
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A third sero-negative 63 year-old patient presented with locally advanced vulva carcinoma with a 
previous history of a cerebro-vascular accident two years previously; she was diabetic, hypertensive with 
a right big toe amputation secondary to vascular disease. She also had a 30 pack-year smoking history. 
The patient was treated with external beam therapy 45Gy in 25 fractions and a boost dose of 21.6 Gy/12 
fractions without concurrent chemotherapy with residual disease which was later surgically excised. 
 
The mean treatment time for the sero-negative patients was 6.11 weeks (Range: 3 to 7 weeks) and the 
total treatment dose in 2 gray equivalent (EQD2) was 49.29 Gy. 
 
Severe myelo-suppression during treatment was absent. Three patients developed moist desquamation 
during chemo-radiation therapy and had their treatments delayed. Overall, 25 patients completed the 
prescribed treatment plan and were evaluable for response (see Tables).  Toxicity was acceptable for stage 
and location of disease. 
 
Co-morbid chronic conditions and opportunistic infections were also noted. In the HIV positive group, 
one patient was on treatment for Type 2 Diabetes Mellitus, another for pulmonary tuberculosis while 
another one was being treated for hypertension. 
 
In the HIV negative subgroup, a total of eleven patients had been on treatment for hypertension including 
one who had suffered a cerebro-vascular accident two years earlier; all had their blood pressure well 
controlled. 
 
Three patients had been previously treated for pulmonary tuberculosis and another was on Type 2 
Diabetes Mellitus treatment. 
 
One should note that these patients were medically stabilized before and during treatment to optimize the 
treatment outcome. 
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Chapter 4: 
Discussion 
 
Accelerating the increase of cancer in developing countries has been the HIV/AIDS pandemic the 
epicenter of which is Sub-Saharan Africa, where close to 70% of the world’s HIV positive population 
lives only exacerbating this situation. 
 
It is critical to evaluate current treatment options for vulva cancer and to develop future options 
appropriate to the diseases seen in the background of HIV infection and competing comorbidities. 
 
Vulva cancer is a rare gynecological malignancy which carries a heavy burden of morbidity. Its treatment 
is challenging, especially given the frequent background of HIV infection which often presents with 
competing comorbidities and conditions. 
 
A critical concern in a resource limited environment is that excess toxicity does not just translate to 
morbidity as it does in resource-replete care settings, but can easily lead to mortality. 
 
In our study, patients were offered the same treatments for their disease regardless of their HIV status and 
good treatment compliance was achieved. 
 
One notable issue was that most of the sero-positive patients were black (71%) and presented at a 
significantly younger age than the sero-negative patients. This latter observation is consistent with the 
findings of Moodley et al. (2005) who found that these sero-positive patients presented, on average,  at 
least ten years younger than sero-negative ones. This suggests that the sero-positive patients were infected 
at a younger age which is consistent with the South African HIV/AIDS prevalence and demographic data. 
This suggestion may need to be investigated further to introduce interventions that could mitigate against 
this burden 
(8) 
. 
 
Chemotherapy was well tolerated in both the sero-positive and sero-negative subgroups; this was mostly 
due to the prudent selection process whereby patients only received concurrent chemo-radiation if they 
had a good performance status and organ function and were already on antiretroviral therapy with CD4 
counts of over 200 cells per cubic millimeter as per the Western Cape guidelines.  
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Cutaneous toxicity was more apparent in the HIV positive subgroup but the mechanisms which resulted 
in these reactions are not clear. 
 
As per the findings of the Gynecologic Oncology Group (GOG) trials and related anal cancer studies, 
chemo-radiation was observed to have better outcomes than radiation therapy alone  
(12,13)
. 
 
Concurrent chemotherapy could possibly achieve the same local control rate at a lower toxicity 
than a treatment plan  employing higher total doses of radiation; this has been extrapolated from Ca 
cervix studies
 (16)
. 
  
When used in the treatment of squamous cell carcinoma of the anus, cisplatin plus 5-fluorouracil 
chemo-radiation yielded results superior to radiation therapy alone, and local control rates were 
comparable to 5-fluorouracil and mitomycin-C, suggesting that chemo-radiation is superior to 
radiotherapy alone 
 (23,24)  
. 
 
There is evidence that the prolongation of overall treatment time may be counterproductive to overall 
outcome; this is based on the  radiobiology studies of head and neck squamous cell carcinoma. Thus, any 
extending, interruption or postponement of treatment should only be allowed following the development 
of severe acute skin reactions, and such delay should be for the shortest duration possible as described by 
Bese et al 
(25)
. 
 
In the Tygerberg Hospital, the practice was to administer weekly cisplatin at 40mg/m
2
 , to a maximum 
dose of 70mg weekly, to patients who were carefully judged to be capable of tolerating therapy.  There 
were no significant differences between the two groups treated with chemo-radiation, concerning 
increased toxicity such as neutropenic sepsis, acute renal failure and severe gastroenteritis. 
 
Treatment gaps were minimized and planned breaks were avoided. 
 
The data reported on, in this thesis, were collected as part of routine clinical management. The current 
medical literature on vulva cancer still leaves unresolved the issues of whether concurrent  
chemotherapy improves treatment results and if so, whether there are any significant differences in the 
outcomes for sero-positive and sero-negative patients. 
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These findings call for the need to create a research and care infrastructure sufficient to meet this 
challenge of providing effective treatment in resource-constrained settings where vulva cancer remains an 
under-recognized and under-resourced cause of morbidity and mortality. There is also a need for a prudent 
goal-directed management strategy. 
Strengths and Limitations 
This is a retrospective study with a limitation of non-uniform reporting of treatment side effects and in 
some cases there are missing data such as follow-up CD4 Counts. 
The boost dose and response of the vulva epithelial carcinoma to radiation therapy are not clearly 
identified as patients received various boost doses to the tumour. 
New radiotherapy techniques such as Intensity Modulated Radiation Therapy (IMRT) and Image Guided 
Radiation Therapy (IGRT) have evolved and if these techniques are accessible then they could change the 
toxicity profile of treatment of locally advanced vulva cancer in both subsets of patients. 
In 2009, the International Federation of Gynecology and Obstetrics (FIGO)
(26) 
reviewed the staging 
system for carcinoma of the vulva; this did not affect our study to any great extent as it focused on locally 
advanced disease. 
The quality of life of patients was not evaluated in this retrospective study. 
The follow-up time was too brief and the number of patients was too small to allow for an in-depth 
analysis of survival or patterns of failure and to make a comparison between HIV positive and negative 
patients. 
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Recommendations 
 
Future prospective trials should attempt to identify the optimum sequence of chemo-radiotherapy and 
surgery for the treatment of locally-advanced carcinoma of the vulva in patients presenting with HIV. The 
objective would be define, better, the optimal combination of radiation and chemotherapy doses that 
could lead to optimal local control and function preservation for that specific group of patients. 
The rarity of vulva cancer calls for prospective randomized clinical trials to be conducted in the setting of 
multi-centre, institutional and even international collaboration to study the disease further. 
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Chapter 5 
Conclusion 
The number of patients in this study was relatively small. Also, there is relative dearth in literature 
addressing the treatment outcomes for HIV positive patients with vulva cancer.  However, the results of 
the study provide no reason to suggest that the approach towards treatment of HIV positive patients 
stabilized on HAART should differ from their HIV negative counterparts. 
 
Treatment options in the resource-constrained setting of the Tygerberg Hospital are limited, both by 
financial constraints as well as by the need to avoid toxicity, which is associated with high morbidity. 
 
In the developed world, vulva carcinoma is generally encountered in older patients and at an earlier stage 
than the patients reported on in this study.  The findings of this study have demonstrated acceptable and 
comparable treatment outcomes for the disease stages observed, with both objective responses and 
clinical benefit observed in a resource-limited care setting. 
 
This conclusion could be used as the basis for a reasonable baseline model in the development of policies 
when setting up new radiotherapy services in resource-constrained settings. It could incentivize the 
further refinement of local policies and possibly clinical care protocols to improve outcomes in the 
developing world, which faces the challenges of scarce resources, with younger patients typically 
presenting at a more advanced stage of the disease. Also, as the study has shown, many patients with 
vulva cancer in the developing world also present with HIV infection which could now be considered to 
be a chronic long-term disease when treated with anti-retroviral therapy; as a result, this type of patient 
typically has a longer life-expectancy than in the past and this needs to be taken into account when 
prescribing treatment. 
 
Radiotherapy remains central to the treatment of vulva cancer and in view of its importance, further 
prospective randomized clinical trials are needed to identify the optimal radiation techniques and dosing. 
Those trials could examine possible novel chemotherapy agents, doses, newer anti-retrovirals and their 
optimization in terms of a concomitant or sequential approach in combating vulva cancer. 
Radiotherapy should be avoided in those instances of early vulva cancer which can be surgically 
managed. 
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The data obtained during this study should promote a better understanding of the disease processes in  
HIV and Cancer at biological and clinical level , including  treatment processes, objective quality of life 
assessments that will contribute to the design of future prospective clinical trials in this patient 
population. 
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